We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+13.67%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.92B
AUM Growth
+$890M
Cap. Flow
+$570M
Cap. Flow %
14.53%
Top 10 Hldgs %
70.03%
Holding
46
New
6
Increased
11
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$84.2M
2
BAX icon
Baxter International
BAX
+$70.8M
3
WBA
Walgreens Boots Alliance
WBA
+$40.2M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$34.9M
5
MDT icon
Medtronic
MDT
+$26.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$148M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$104M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$66.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$65.3M
5
XRAY icon
Dentsply Sirona
XRAY
+$60.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.63%
2 Consumer Staples 1.06%
3 Consumer Discretionary 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$951M 24.23%
+2,000,000
New +$891M
UHS icon
2
Universal Health Services
UHS
$10.2B
$285M 7.26%
1,870,000
-130,000
-7% -$17.5M
THC icon
3
Tenet Healthcare
THC
$22.2B
$283M 7.21%
3,745,000
+95,000
+3% +$6.02M
ZBH icon
4
Zimmer Biomet
ZBH
$18.8B
$234M 5.97%
1,925,000
+75,000
+4% +$8.37M
VTRS icon
5
Viatris
VTRS
$20.8B
$200M 5.11%
18,500,000
-1,500,000
-8% -$14.4M
BAX icon
6
Baxter International
BAX
$12.8B
$193M 4.93%
5,000,000
+2,000,000
+67% +$70.8M
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
$183M 4.66%
7,000,000
+1,800,000
+35% +$40.2M
MDT icon
8
Medtronic
MDT
$112B
$152M 3.88%
1,850,000
+350,000
+23% +$26.7M
MYGN icon
9
Myriad Genetics
MYGN
$476M
$146M 3.72%
7,635,000
+1,000,000
+15% +$17.3M
GMED icon
10
Globus Medical
GMED
$11.1B
$120M 3.06%
2,250,000
+525,000
+30% +$25.6M
PFE icon
11
CALL
Pfizer
PFE
$143B
$113M 2.88%
3,920,000
-3,580,000
-48% -$108M
PTCT icon
12
PTC Therapeutics
PTCT
$6.18B
$110M 2.81%
4,000,000
+600,000
+18% +$13.7M
BKD icon
13
Brookdale Senior Living
BKD
$3.55B
$90.2M 2.3%
15,500,000
-2,500,000
-14% -$11.7M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$16.1B
$83M 2.12%
+675,000
New +$84.2M
GSK icon
15
GSK
GSK
$107B
$80.6M 2.05%
2,175,000
-675,000
-24% -$24.2M
SEM
16
DELISTED
Select Medical
SEM
$79.9M 2.04%
6,310,400
– –
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.64B
$77.1M 1.97%
800,000
– –
PRGO icon
18
Perrigo
PRGO
$1.44B
$59.5M 1.52%
1,850,000
– –
ZIMV
19
DELISTED
ZimVie
ZIMV
$57.7M 1.47%
3,250,000
– –
IONS icon
20
Ionis Pharmaceuticals
IONS
$8.93B
$43.8M 1.12%
865,000
-1,385,000
-62% -$66.3M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.46B
$43M 1.1%
+900,000
New +$34.9M
OSUR icon
22
OraSure Technologies
OSUR
$273M
$34.9M 0.89%
4,250,000
– –
COLL icon
23
Collegium Pharmaceutical
COLL
$1.18B
$32.3M 0.82%
1,050,000
– –
HLF icon
24
Herbalife
HLF
$1.3B
$30.5M 0.78%
2,000,000
-850,000
-30% -$11.7M
QDEL icon
25
QuidelOrtho
QDEL
$1.13B
$29.5M 0.75%
400,000
+75,000
+23% +$5.07M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Camber Capital Management held 46 positions worth $3.92B, up 29% from $3.03B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Camber Capital Management deployed $570M of net new capital in Q4 2023, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 675,000 shares worth $83M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 88% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $66.3M trimmed.

  • Camber Capital Management's largest Q4 2023 buy was Jazz Pharmaceuticals: 675,000 shares worth $83M.
  • Camber Capital Management added most to Baxter International in Q4 2023, an estimated $70.8M increase.
  • Camber Capital Management's biggest Q4 2023 reduction was Ionis Pharmaceuticals, cutting an estimated $66.3M.
  • Camber Capital Management fully exited Sanofi in Q4 2023, selling an estimated $148M.
  • Camber Capital Management's ten largest holdings make up 70% of its $3.92B portfolio in Q4 2023.
  • Camber Capital Management opened 6 new positions and closed 8 in Q4 2023.
  • Camber Capital Management's portfolio value rose 29% quarter-over-quarter to $3.92B.

Based on Camber Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.